Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.92 USD
Change Today +0.02 / 0.51%
Volume 453.7K
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

tetralogic pharmaceuticals c (TLOG) Snapshot

Open
$3.89
Previous Close
$3.90
Day High
$4.07
Day Low
$3.82
52 Week High
06/17/14 - $6.49
52 Week Low
10/13/14 - $3.51
Market Cap
112.1M
Average Volume 10 Days
311.3K
EPS TTM
$-1.59
Shares Outstanding
28.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TETRALOGIC PHARMACEUTICALS C (TLOG)

Related News

No related news articles were found.

tetralogic pharmaceuticals c (TLOG) Related Businessweek News

No Related Businessweek News Found

tetralogic pharmaceuticals c (TLOG) Details

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. Its clinical-stage product candidate, Birinapant, is in Phase II clinical trial administered with azacitidine for the treatment of myelodysplastic syndromes. The company’s pre-clinical programs also comprise Phase I/II open-label, non-randomized clinical trial of Birinapant administered with conatumumab in third-line ovarian cancer; and Phase I clinical trial of Birinapant in subject with chronic Hepatitis B virus. In addition, its clinical-stage product candidate, suberohydroxamic acid 4-methoxycarbonyl phenyl ester, is in Phase II clinical trial for the treatment of early-stage cutaneous T-cell lymphoma. The company has collaboration with Amgen, Inc. for exploring the combination of Birinapant administered with Amgen’s TRAIL receptor agonist antibody, conatumumab. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

30 Employees
Last Reported Date: 02/26/15
Founded in 2001

tetralogic pharmaceuticals c (TLOG) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $562.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $438.0K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $438.0K
Senior Vice President of Strategic Transactio...
Total Annual Compensation: $429.8K
Chief Scientific Officer
Total Annual Compensation: $511.0K
Compensation as of Fiscal Year 2014.

tetralogic pharmaceuticals c (TLOG) Key Developments

TetraLogic Pharmaceuticals Mulls Acquisitions

TetraLogic Pharmaceuticals Corporation (NasdaqGM:TLOG) is seeking acquisitions. TetraLogic announces pricing of $25 million of public offering. TetraLogic Pharmaceuticals said in Sec Filling, “TetraLogic anticipates using the net proceeds from the offering for general corporate purposes, including working capital, continued development of its product candidate pipeline, acquisitions and other business opportunities.”

TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B

TetraLogic Pharmaceuticals Corporation announced that research describing birinapant's preclinical activity in a mouse model of chronic human hepatitis B virus (HBV) has been published in the journal Proceedings of the National Academy of Sciences. The publication reports preclinical studies performed at the Walter and Eliza Hall Institute of Medical Research (WEHI), Melbourne, Australia in collaboration with TetraLogic Pharmaceuticals. In studies performed by Dr. Marc Pellegrini and his colleagues in mouse models of human hepatitis B, administration of birinapant resulted in loss of HBV-DNA, loss of HBsAg and the appearance of anti-HBsAg antibodies. A second paper describes similar results in mice where the targets of birinapant, cIAP1 and cIAP2, were ablated in the liver ("knock-out mice"). That result provides independent genetic confirmation of birinapant's mechanism of action. These experiments provided the scientific rationale for TetraLogic's ongoing multiple ascending dose study of birinapant in subjects with chronic HBV. The trial is being conducted in subjects over the age of 18 with chronic HBV who are receiving treatment with either tenofovir or entecavir and who are HBsAg positive. The trial is expected to enroll approximately 6 cohorts of 8 subjects each, who will receive 4 weekly treatments with either birinapant or placebo in a 3:1 ratio. The study is being conducted at multiple clinical sites in Australia. Although predominantly a safety and tolerability study, patients will also be monitored for reductions in HBsAg and formation of antibodies to HBsAg as indications of therapeutic activity.

TetraLogic Pharmaceuticals Corporation and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA(R) (Pembrolizumab) in Solid Tumors

TetraLogic Pharmaceuticals Corporation and Merck announced that they have entered into an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic's SMAC-mimetic, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is expected to begin in late 2015. KEYTRUDA and birinapant target different elements of cancer's block against the immune system. TetraLogic's birinapant (TL32711) is a potent, bivalent SMAC-mimetic that binds with differential affinity to multiple members of the IAP family in order to re-establish the immune system's ability to kill abnormal cells via an extracellular TNF signal. Merck's KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. The proposed collaboration is based on preclinical data that suggest SMAC-mimetics have the potential to enhance existing immuno-oncology agents, such as KEYTRUDA. Under the terms of the agreement, TetraLogic and Merck, through subsidiaries, will collaborate on an initial Phase 1 dose-escalation study of birinapant in combination with KEYTRUDA in patients with relapsed or refractory solid tumors. TetraLogic will sponsor and fund the study and Merck will provide KEYTRUDA. The companies have formed a Joint Development Committee to collaboratively oversee the conduct of the study. Results from the study will be used to determine the path for further clinical development of the combination.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TLOG:US $3.92 USD +0.02

TLOG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TLOG.
View Industry Companies
 

Industry Analysis

TLOG

Industry Average

Valuation TLOG Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TETRALOGIC PHARMACEUTICALS C, please visit www.tetralogicpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.